[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志,2021,44(3):170-205.
[2] Wang C, Zhou J, Wang J, et al.Progress in the mechanism and targeted drug therapy for COPD[J]. Signal Transduct Target Ther,2020, 5(1): 248.
[3] Wang Y, Xu J, Meng Y, et al.Role of inflammatory cells in airway remodeling in COPD[J]. Int J Chron Obstruct Pulmon Dis,2018,13: 3341-3348.
[4] Ozcakir S, Sigirli D, Ursavas A, et al.COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2441-2448.
[5] Chen YW, Ramsook AH, Coxson HO, et al.Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis[J]. Chest,2019,156(6): 1092-1110.
[6] Pascual-Guardia S, Badenes-Bonet D, Martin-Ontiyuelo C, et al.Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures[J]. Int J Chron Obstruct Pulmon Dis,2017, 12: 1837-1845.
[7] Okazaki R, Watanabe R, Inoue D.Osteoporosis Associated with chronic obstructive pulmonary disease[J]. Chron Obstruct Pulmon Dis,2016, 23(3): 111-120.
[8] Clynes MA, Gregson CL, Bruyere O, et al.Osteosarcopenia: Where Osteoporosis and Sarcopenia Collide[J]. Rheumatol (Oxford),2021, 60(2): 529-537.
[9] Schaper F,Rose-John S.Interleukin-6: Biology, signaling and strategies of blockade[J]. Cytokine Growth Factor Rev,2015, 26(5):475-487.
[10] Kany S, Vollrath JT, Relja B.Cytokines in Inflammatory Disease[J]. Int J Mol Sci,2019, 20(23): 6008.
[11] Hunter CA,Jones SA.IL-6 as a keystone cytokine in health and disease[J]. Nat Immunol, 2015, 16(5):448-457.
[12] Clynes MA, Gregson CL, Bruyère O, et al.Osteosarcopenia: where osteoporosis and sarcopenia collide[J]. Rheumatology (Oxford),2021, 60(2): 529-537.
[13] Krick S, Helton ES, Easter M, et al.ST6GAL1 and α2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease[J]. Front Immunol,2021,12: 693149.
[14] Celli BR, Locantore N.Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2012,185(10): 1065-72.
[15] Zhuang Y, Yan Y, Yang X, et al.Osteoporosis in a Rat Model Co-Exposed to Cigarette Smoke and Intermittent Hypoxia[J]. Int J Chron Obstruct Pulmon Dis,2020, 15: 2817-2825.
[16] 张文强,罗俊超,梁丹,等. 慢性阻塞性肺疾病合并骨质疏松症的研究进展[J]. 实用心脑肺血管病杂志,2021,29(5):14-17.
[17] Infante M, Fabi A, Cognetti F, et al.RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives[J]. J Exp Clin Cancer Res,2019, 38(1): 12.
[18] Boyce BF, Xing L.Functions of RANKL/RANK/OPG in bone modeling and remodeling[J]. Arch Biochem Biophys,2008, 473(2): 139-146.
[19] Dougall WC, Glaccum M, Charrier K, et al.RANK is essential for osteoclast and lymph node development[J]. Genes Dev,1999, 13(18): 2412-2424.
[20] 胡磊,张大卫,江浩洋,等. 慢性阻塞性肺疾病患者系统性炎症水平与肺气肿程度和骨密度改变相关性研究[J]. 中华结核和呼吸杂志,2021,44(3):213-217.
[21] Osta B, Benedetti G, Miossec P.Classical and Paradoxical Effects of TNF-α on Bone Homeostasis[J]. Front Immunol,2014, 5: 48.
[22] Infante M, Fabi A, Cognetti F, et al.RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives[J]. J Exp Clin Cancer Res, 2019, 38(1): 12.
[23] Chen Y, Bai P, Liu L, et al.Increased RANKLexpression in peripheral T cells is associated with decreased bone mineral density in patients with COPD[J]. Int J Mol Med,2016, 38(2): 585-593.
[24] AlQranei MS, Senbanjo LT, Aljohani H, et al. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling[J]. BMC Immunol,2021, 22(1): 23.
[25] Yu H.Targeting S1PRs as a Therapeutic Strategy for Inflammatory Bone Loss Diseases-Beyond Regulating S1P Signaling[J]. Int J Mol Sci,2021, 22(9): 4411.
[26] Xiong J, Zhou L, Tian J, et al.Cigarette Smoke-Induced Lymphoid Neogenesis in COPD Involves IL-17/RANKL Pathway[J]. Front Immunol,2021, 11: 588522.
[27] Gao X, Wu Q, Zhang X.Salvianolate Ameliorates Osteopenia and Improves Bone Quality in Prednisone-Treated Rheumatoid Arthritis Rats by Regulating RANKL/RANK/OPG Signaling[J]. Front Pharmacol,2021, 12: 710169.
[28] Castello LM, Raineri D, Salmi L, et al.Osteopontin at the Crossroads of Inflammation and Tumor Progression[J]. Mediators Inflamm,2017. doi: 10.1155/2017/4049098.
[29] Orsi G, Cseh T, Hayden Z.Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light[J]. Mult Scler Relat Disord, 2021, 51: 102923.
[30] Wang J, Huang J, Zhu M, et al.Osteopontin potentiates PM-induced IL-1α and IL-1β production via the ERK/JNK signaling pathway[J]. Ecotoxicol Environ Saf,2019, 171: 467-474.
[31] Hao C, Cui Y, Chang S.OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase[J]. Sci Rep,2019, 9(1): 18101.
[32] 张宏华,肖芸,邓春燕,等. 血清骨桥蛋白在慢性阻塞性肺疾病患者中的表达及临床意义[J]. 中国煤炭工业医学杂志,2010,13(11):1609-1610.
[33] 马金平,黄靓,张斌. 骨桥蛋白与慢性阻塞性肺疾病的相关性研究[J]. 检验医学与临床,2015, 12(17):2631-2633.
[34] 樊梅,王宋平. 骨桥蛋白与肺部疾病关系的研究进展[J]. 中国呼吸与危重监护杂志,2017,16(5):525-528.
[35] Si J, Wang C, Zhang D, et al.Osteopontin in Bone Metabolism and Bone Diseases[J]. Med Sci Monit,2020, 26: e919159.
[36] Lamort AS, Giopanou I, Psallidas I, et al.Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight[J]. Cells,2019, 8(8): 815.
[37] 陈思敏,邓伟民,魏秋实,等. 骨桥蛋白与骨质疏松症相关性研究进展[J]. 解放军预防医学杂志,2014,32(4):373-375.
[38] Fodor D, Bondor C, Albu A, et al.The value of osteopontin in the assessment of bone mineral density status in postmenopausal women[J]. J Investig Med,2013, 61(1): 15-21.
[39] Ozcakir S, Sigirli D, Ursavas A, et al.COPD and Osteoporosis: Associated Factors in Patients Treated with Inhaled Corticosteroids[J]. Int J Chron Obstruct Pulmon Dis,2020, 15: 2441-2448.
[40] 刘伟新,苗亚飞,刘丁君. 慢性阻塞性肺疾病患者合并骨质疏松的患病情况及危险因素[J]. 中国卫生工程学,2018,17(3):465-467. |
